
<news><entry author="By Andrew Ward, Arash Massoudi and Miles Johnson in London" date="May 22, 2014 7:59 pm" url="http://www.ft.com/cms/s/0/a5658c12-e1cb-11e3-b7c4-00144feabdc0.html"><headline>Big AstraZeneca investors push for further talks with Pfizer</headline><body><![CDATA[Big shareholders in AstraZeneca have told the UK drugmaker they want the board to reopen takeover talks with Pfizer as early as August, after accepting that a deal is unlikely to be agreed with its US rival before Monday''s bid deadline.</p>
BlackRock and Schroders are among those that have told AstraZeneca they want the company to take a fresh look at a possible deal after the three-month cooling-off period required under UK takeover rules.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By James Politi in Wilmington, Delaware" date="May 22, 2014 7:37 am" url="http://www.ft.com/cms/s/0/c194e85e-dd40-11e3-8546-00144feabdc0.html"><headline>Delaware fears job losses if Pfizer returns to chase AstraZeneca</headline><body><![CDATA[AFP]]> </body></entry><entry author="By Arash Massoudi and Andrew Ward in London" date="May 21, 2014 7:33 pm" url="http://www.ft.com/cms/s/0/4d6fba64-e108-11e3-b59f-00144feabdc0.html"><headline>AstraZeneca deal in injury time'' after final Pfizer offer</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Andrew Ward, Miles Johnson and Arash Massoudi in London" date="May 21, 2014 4:07 pm" url="http://www.ft.com/cms/s/0/d4f46e04-e0f3-11e3-a934-00144feabdc0.html"><headline>AstraZeneca battles to shore up support for Pfizer rejection</headline><body><![CDATA[AstraZeneca is battling to shore up shareholder support for its decision to resist Pfizer''s 69.4bn takeover approach as the US drugmaker makes a last-ditch push to revive the stalled deal.</p>
Both companies were engaged in intensive lobbying of investors on Wednesday with just five days to go before the deadline for Pfizer to secure AstraZeneca''s backing for a deal or walk away.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Andrew Ward, Pharmaceuticals Correspondent" date="May 20, 2014 7:32 pm" url="http://www.ft.com/cms/s/0/05e0389c-e039-11e3-9534-00144feabdc0.html"><headline>Pfizer strategy in spotlight after failure of AstraZeneca deal</headline><body><![CDATA[EPA<p>Ian Read, Chairman and Chief Executive of Pfize</p>]]> </body></entry><entry author="By Sam Fleming" date="May 20, 2014 1:47 pm" url="http://www.ft.com/cms/s/0/01eee76e-e012-11e3-b709-00144feabdc0.html"><headline>Q&amp;A: Pfizer clarifies bid intentions on AstraZeneca</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Andrew Ward and Arash Massoudi in London and Ed Hammond in New York" date="May 21, 2014 12:29 am" url="http://www.ft.com/cms/s/0/05a84e26-e004-11e3-b709-00144feabdc0.html"><headline>Pfizer scrambles to keep Astra bid alive</headline><body><![CDATA[Getty]]> </body></entry><entry author="By Miles Johnson and Andrew Ward in London" date="May 19, 2014 8:45 pm" url="http://www.ft.com/cms/s/0/af8237fc-df70-11e3-8842-00144feabdc0.html"><headline>Astra investors split on Pfizer''s rejection</headline><body><![CDATA[Shareholders in AstraZeneca were split by the company''s decision to reject a final 69bn offer from Pfizer, with some arguing that ts management had betrayed investors while others praised the board''s faith in its long term prospects.</p>
As AstraZeneca''s shares tumbled following the rejection statement, some large investors argued that Pascal Soriot, chief executive, should have allowed them to make up their own mind over the latest offer.
</p>
]]> </body></entry><entry author="By Andrew Ward and Miles Johnson in London and Ed Hammond in New York" date="May 19, 2014 7:30 pm" url="http://www.ft.com/cms/s/0/dab786fa-df77-11e3-8842-00144feabdc0.html"><headline>Pfizer snub triggers recrimination at Astra</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Arash Massoudi and Andrew Ward in London and Ed Hammond in New York" date="May 19, 2014 6:35 pm" url="http://www.ft.com/cms/s/0/f0e0e56c-df76-11e3-8842-00144feabdc0.html"><headline>AstraZeneca and Pfizer: High-stakes brinkmanship ends with recriminations</headline><body><![CDATA[When Ian Read flew back across the Atlantic on Thursday evening after a four-day stay in London, he was feeling cautiously optimistic about pulling off one of the biggest pharmaceuticals deals in history.</p>
The chairman and chief executive of Pfizer had survived two days of hostile questioning about his takeover proposal from UK lawmakers and meetings with shareholders in AstraZeneca had left him confident they were open to a deal. </p>
]]> </body></entry><entry author="By Elizabeth Rigby, Deputy Political Editor" date="May 19, 2014 3:36 pm" url="http://www.ft.com/cms/s/0/bfcaeabe-df57-11e3-86a4-00144feabdc0.html"><headline>Labour keeps up pressure on PM over Pfizer</headline><body><![CDATA[Labour on Monday welcomed AstraZeneca''s rejection of Pfizer''s final 69bn bid approach as the opposition party again criticised Prime Minister David Cameron for acting as a cheerleader for the US drugmaker. </p>
Chuka Umunna, shadow business secretary, said the UK pharmaceutical company''s decision to reject the improved offer vindicated Labour''s misgivings over the deal, as he accused the prime minister of failing to act to protect British science and jobs. </p>
]]> </body></entry><entry author="By Sam Fleming and Lindsay Whipp" date="May 19, 2014 12:27 pm" url="http://www.ft.com/cms/s/0/907ff28e-df31-11e3-86a4-00144feabdc0.html"><headline>Q&amp;A: Is the possibility of a Pfizer-AstraZeneca deal now dead?</headline><body><![CDATA[Pfizer is redefining final by making its second final offer to acquire AstraZeneca, which the UK company has rejected. Does this mean that the possibility of a Pfizer-AstraZeneca combination is now dead? </p>
The US pharmaceutical company''s 55-a-share proposal did not meet AstraZeneca''s demand that any offer is more than 10 per cent above the level contained in Pfizer''s Friday proposal of 53.50 a share. It represented a 45 per cent premium from its undisturbed share price on May 2. </p>
Pfizer''s proposal for AstraZeneca in numbers

Offer
Amount per share
Values Astra at...
% higher than final'' offer 1
Composition

Final'' offer 1
53.50
67.5bn
N/A
Cash: 21.57 (40%)</p>
Pfizer Shares: 1.845 (60%)</p>

Final'' offer 2
55.00
69.4bn
2.8%
Cash: 24.76 (45%)</p>
Pfizer Shares: 1.747 (55%)</p>

*Astra''s demands
More than 58.85
74.3bn
More than 10%
Not made explicit
Current valuation
N/A
About 52bn following a 13% intraday decline in its share price on Monday
N/A
N/A


]]> </body></entry><entry author="By Andrew Ward, Pharmaceuticals Correspondent" date="May 19, 2014 9:33 am" url="http://www.ft.com/cms/s/0/9762b966-df26-11e3-86a4-00144feabdc0.html"><headline>Timeline: How Pfizer''s approach for AstraZeneca unfolded</headline><body><![CDATA[November 25 2013: Ian Read, Pfizer''s chairman and chief executive, makes the first contact with Leif Johansson, chairman of AstraZeneca, expressing interest in a deal to create the world''s biggest pharmaceuticals group. Mr Johansson expresses confidence in AstraZeneca''s prospects as a standalone company but agrees to meet for exploratory talks.</p>
January 5 2014: Mr Johansson and Pascal Soriot, AstraZeneca chief executive, lead a small delegation to New York. At this meeting, Mr Read makes a preliminary offer worth 46.61 a share, 30 per cent in cash and the rest in Pfizer shares.</p>
]]> </body></entry><entry author="By Andrew Ward, Miles Johnson and Arash Massoudi in London and Ed Hammond in New York" date="May 19, 2014 1:06 pm" url="http://www.ft.com/cms/s/0/41e4cb30-df23-11e3-86a4-00144feabdc0.html"><headline>AstraZeneca shares tumble as it snubs Pfizer''s final'' bid</headline><body><![CDATA[Bloomberg<p>Pascal Soriot, AstraZeneca CEO, and Ian Read, CEO of Pfizer</p>]]> </body></entry><entry author="By Ed Hammond in New York and Andrew Ward and Arash Massoudi in London" date="May 19, 2014 2:28 am" url="http://www.ft.com/cms/s/0/3b5e8122-ded1-11e3-9640-00144feabdc0.html"><headline>AstraZeneca prepares to reject Pfizer''s final'' 69bn offer</headline><body><![CDATA[AstraZeneca is preparing to reject a 69bn takeover bid by rival drugmaker Pfizer just hours after its US suitor said it would walk away if its offer were rebuffed, putting into doubt a deal that would be the largest foreign takeover of a UK company.</p>
The 55-per-share bid, upped from 50 two weeks ago, was viewed by key members of AstraZeneca''s management team and its board of directors as falling short of properly valuing the company, according to people familiar with the matter. </p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Andrew Ward in New York and Arash Massoudi in London" date="May 16, 2014 11:17 pm" url="http://www.ft.com/cms/s/0/c1c90cca-dd3f-11e3-8546-00144feabdc0.html"><headline>Pfizer seeks breast cancer drug approval</headline><body><![CDATA[Getty]]> </body></entry><entry author="By George Parker and Caroline Binham in London and Andrew Ward in New York" date="May 16, 2014 8:10 pm" url="http://www.ft.com/cms/s/0/82af4d74-dd0d-11e3-8546-00144feabdc0.html"><headline>Labour raises political stakes with threat to block Pfizer bid</headline><body><![CDATA[<p>Shadow business secretary Chuka Umunna</p>]]> </body></entry><entry author="By Elizabeth Rigby and George Parker in London and Alex Barker in Brussels" date="May 15, 2014 8:34 pm" url="http://www.ft.com/cms/s/0/d7447bc4-dc41-11e3-a33d-00144feabdc0.html"><headline>Cameron faces strategy test on Pfizer bid</headline><body><![CDATA[Britain has been scathing about the French government''s new decree allowing it to defend strategic industries from foreign takeovers; David Cameron''s government is about to be tested on whether it has a better approach.</p>
After a week of intense political activity at Westminster, Mr Cameron is braced for what the market widely believes is inevitable: a formal bid by Pfizer, the US pharmaceuticals group, for Britain''s AstraZeneca.</p>
]]> </body></entry><entry author="By Richard Milne, Nordic Correspondent" date="May 15, 2014 2:05 pm" url="http://www.ft.com/cms/s/0/143ea146-dc27-11e3-8511-00144feabdc0.html"><headline>Swedish leader speaks out against Pfizer approach for AstraZeneca</headline><body><![CDATA[Simon Hoegsberg<p>Stefan Lfven</p>]]> </body></entry><entry author="By Ed Hammond in New York and Elizabeth Rigby and Miles Johnson in London" date="May 14, 2014 8:14 pm" url="http://www.ft.com/cms/s/0/407afc08-db89-11e3-a460-00144feabdc0.html"><headline>AstraZeneca investors express interest in higher Pfizer offer</headline><body><![CDATA[Bloomberg<p>Pascal Soriot, AstraZeneca CEO, and Ian Read, CEO of Pfizer</p>]]> </body></entry><entry author="By Andrew Jack and Elizabeth Rigby" date="May 14, 2014 8:37 pm" url="http://www.ft.com/cms/s/0/4b0a73d6-db45-11e3-94ad-00144feabdc0.html"><headline>Pfizer says takeover would not delay drug development</headline><body><![CDATA[The chief executive of Pfizer has said drugs development would if anything be accelerated if his company took over AstraZeneca, rejecting criticism from the UK drugmaker that a takeover could cost lives by delaying the launch of new medicines. </p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By James Politi in Washington" date="May 14, 2014 3:16 am" url="http://www.ft.com/cms/s/0/32ca5d36-db09-11e3-9a27-00144feabdc0.html"><headline>Top Republican rebuffs quick Pfizer tax legislation</headline><body><![CDATA[The top Republican tax writer in the US Senate has quashed the idea of a quick move in Congress targeting tax inversion deals in the wake of Pfizer''s $106bn bid for AstraZeneca, saying the problem should be solved through broader tax reform.</p>
Orrin Hatch of Utah, his party''s senior member on the Senate finance committee, on Tuesday sent the clearest signal yet that Republicans will not embrace proposals by congressional Democrats and the White House to enact legislation that would make it much harder for companies such as Pfizer to redomicile overseas for tax reasons.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Andrew Ward and Elizabeth Rigby" date="May 13, 2014 8:32 pm" url="http://www.ft.com/cms/s/0/dfadf9f4-dab9-11e3-9a27-00144feabdc0.html"><headline>Pfizer''s AstraZeneca bid: How MPs probed proposed deal</headline><body><![CDATA[PA<p>Pfizer chief Ian Read gives evidence to the Commons business committee on Tuesday</p>]]> </body></entry><entry author="By Brian Groom, Business and Employment Editor" date="May 13, 2014 6:39 pm" url="http://www.ft.com/cms/s/0/6da9f32c-daae-11e3-9a27-00144feabdc0.html"><headline>Unions call on ministers to block Pfizer bid for AstraZeneca</headline><body><![CDATA[Getty<p>Shut the front door: Jefferies analyst Jeffrey Holford characterised the overly optimistic'' AstraZeneca revenue forecasts on Tuesday as an obvious defence tactic''</p>]]> </body></entry><entry author="By Andrew Ward, Elizabeth Rigby and Miles Johnson" date="May 13, 2014 3:36 pm" url="http://www.ft.com/cms/s/0/10c51cec-daa7-11e3-a448-00144feabdc0.html"><headline>Pfizer says AstraZeneca merger would cut R&amp;D budgets</headline><body><![CDATA[Pfizer has admitted its proposed 63bn takeover of AstraZeneca would result in cuts to research and development budgets and has refused to rule out job cuts.</p>
Ian Read, Pfizer''s chairman and chief executive, emerged relatively unscathed from a grilling by MPs about his plans for the UK''s second-biggest pharmaceuticals company. </p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Jonathan Guthrie" date="Last updated: May 13, 2014 8:11 pm" url="http://www.ft.com/cms/s/0/1a7d9198-da8d-11e3-8273-00144feabdc0.html"><headline>Pfizer tries to sedate 12 angry MPs</headline><body><![CDATA[No revival of Twelve Angry Men has taken such liberties with an original script as the version performed by MPs on Tuesday. Actor-director Adrian Bailey has relocated the jury room drama to the Commons business select committee and placed the defendant  absent in the 1954 teleplay  centre stage in the form of the boss of vast pharmaceuticals group Pfizer.</p>
Another difference (spoiler alert!) is that suspicions of jurors intensify rather than diminish. Under cross-examination, the tycoon dodges commitments to fixed levels of UK research spending if he buys AstraZeneca, a cosy Mom n'' Pop drugs multinational.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Elizabeth Rigby and Andrew Ward" date="May 13, 2014 8:18 pm" url="http://www.ft.com/cms/s/0/c455ba94-da9f-11e3-a448-00144feabdc0.html"><headline>Pfizer concedes AZ takeover means cuts to jobs and R&amp;D</headline><body><![CDATA[PA<p>Pfizer chief Ian Read gives evidence to the Commons business committee on Tuesday</p>]]> </body></entry><entry author="By Andy Sharman and Richard Milne" date="May 13, 2014 8:39 am" url="http://www.ft.com/cms/s/0/66acf760-da66-11e3-a448-00144feabdc0.html"><headline>Pfizer disappointed at AstraZeneca''s lack of engagement</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By James Politi in Washington" date="May 13, 2014 1:07 am" url="http://www.ft.com/cms/s/0/61b0a974-da29-11e3-920f-00144feabdc0.html"><headline>Pfizer declines to commit over US jobs</headline><body><![CDATA[Pfizer declined on Monday to offer firm guarantees to the governors of Maryland and Delaware that it could protect AstraZeneca''s 5,000-strong US workforce in the two states, saying it was premature to judge the impact on jobs of the $106bn takeover bid for its UK rival.</p>
In a letter to Martin O''Malley, Maryland governor, and Jack Markell, Delaware governor, sent on Monday night, Pfizer chairman Ian Read said his company would continue to have research, operational and manufacturing activity in the US with a significant number of employees.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Andrew Ward, Pharmaceuticals Correspondent" date="May 12, 2014 7:21 pm" url="http://www.ft.com/cms/s/0/d8da97b2-d9d9-11e3-b3e3-00144feabdc0.html"><headline>Drug output at heart of Pfizer deal debate</headline><body><![CDATA[At the heart of debate over the future of AstraZeneca is a simple question: In whose hands would the pharmaceutical company''s laboratories produce the most valuable drugs?</p>
UK lawmakers will be probing for an answer on Tuesday when Ian Read, chairman and chief executive of Pfizer, is quizzed by the House of Commons'' business committee over its 63bn approach for its British rival.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Richard Milne, Nordic Correspondent" date="May 11, 2014 7:55 pm" url="http://www.ft.com/cms/s/0/fd358e4c-d901-11e3-837f-00144feabdc0.html"><headline>Pfizer bid for AstraZeneca revives painful memories for Sweden</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Andrew Ward and Helen Warrell in London and Richard Milne in Oslo" date="May 11, 2014 12:30 pm" url="http://www.ft.com/cms/s/0/b6439a54-d8f9-11e3-837f-00144feabdc0.html"><headline>David Cameron cautions against intervention on Pfizer deal</headline><body><![CDATA[David Cameron has warned that Britain must not pull up the drawbridge against foreign investors as Downing Street pushed back against pressure from the opposition Labour party to intervene in Pfizer''s proposed 63bn takeover of AstraZeneca.</p>
The prime minister said the UK benefited massively from its economic openness and insisted the government was making very good progress in seeking job assurances from Pfizer, even without seeking new powers to intervene formally.</p>
His comments came as Ian Read, chairman and chief executive of the US drugmaker, prepared to fly to London on Monday to be quizzed by MPs on his plans for what would be the biggest foreign takeover in UK history.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Richard Milne, Nordic Correspondent" date="May 11, 2014 12:09 pm" url="http://www.ft.com/cms/s/0/22dc41dc-d780-11e3-a47c-00144feabdc0.html"><headline>Swedish research bodies worried'' over Pfizer bid for AstraZeneca</headline><body><![CDATA[The two leading research bodies in Sweden have spoken out against Pfizer''s $110bn bid for AstraZeneca, criticising mergers in the pharmaceutical sector and the US company''s previous form.</p>
The head of the Karolinska Institutet, a Stockholm university that accounts for almost half of the medical research in Sweden, and the chairman of the body behind the Nobel Prizes told the Financial Times of their concerns, in their first public comments on a takeover offer for the Anglo-Swedish company that has raised heckles on both sides of the Atlantic.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Andrew Ward, Pharmaceuticals Correspondent" date="May 10, 2014 12:51 pm" url="http://www.ft.com/cms/s/0/deff4618-d823-11e3-93c7-00144feabdc0.html"><headline>Pfizer launches fight back against AstraZeneca takeover critics</headline><body><![CDATA[Corbis]]> </body></entry><entry author="By Elizabeth Rigby and George Parker" date="May 9, 2014 8:57 pm" url="http://www.ft.com/cms/s/0/5a12c48e-d788-11e3-80e0-00144feabdc0.html"><headline>Political headwinds change for Pfizer chief</headline><body><![CDATA[FT]]> </body></entry><entry author="By James Politi in Washington and Andrew Ward and George Parker in London" date="May 9, 2014 8:43 pm" url="http://www.ft.com/cms/s/0/1cb1ae3a-d755-11e3-a47c-00144feabdc0.html"><headline>US politicians step up Pfizer scrutiny over deal for AstraZeneca</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Elizabeth Rigby, Andrew Ward and Miles Johnson" date="May 8, 2014 11:13 pm" url="http://www.ft.com/cms/s/0/08accbb0-d6cc-11e3-b95e-00144feabdc0.html"><headline>Wellcome Trust raises concerns'' over Pfizer bid for AstraZeneca</headline><body><![CDATA[Britain''s biggest medical research foundation has told the government it has major concerns over Pfizer''s 63bn offer for AstraZeneca, as the Wellcome Trust became the latest powerful voice to weigh in over the mooted deal.</p>
Sir William Castell, the chair of the world''s third largest charitable foundation, and Jeremy Farrar, director of Wellcome Trust, outlined their concerns in a private letter to George Osborne last Friday as the US drugmaker made its opening offer for the UK firm.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By James Politi in Washington" date="May 8, 2014 8:50 am" url="http://www.ft.com/cms/s/0/a7ff8f52-d679-11e3-907c-00144feabdc0.html"><headline>Senator takes aim at tax inversion deals like Pfizer-AstraZeneca</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Vanessa Houlder" date="May 7, 2014 8:48 pm" url="http://www.ft.com/cms/s/0/51344ff4-d5f3-11e3-a239-00144feabdc0.html"><headline>Pfizer case stirs unease at UK tax haven charges</headline><body><![CDATA[PA]]> </body></entry><entry author="By Elizabeth Rigby, Andrew Ward and David Oakley" date="May 7, 2014 2:22 pm" url="http://www.ft.com/cms/s/0/a116ada0-d5df-11e3-83b2-00144feabdc0.html"><headline>Cameron wants more commitments from Pfizer on AstraZeneca deal</headline><body><![CDATA[David Cameron has told Pfizer he wants stronger assurances of its commitment to UK science as he left open the option of extending government powers to intervene in the US drugmaker''s 63bn takeover approach for AstraZeneca.</p>
In a hardening of Downing Street''s attitude towards the deal, the prime minister indicated Pfizer needed to do more to win the government''s blessing for what would be the biggest foreign takeover of a British company.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By James Politi and Richard McGregor in Washington" date="May 7, 2014 11:34 am" url="http://www.ft.com/cms/s/0/2c643a12-d586-11e3-9bca-00144feabdc0.html"><headline>Collective shrug to Pfizer bid reflects Congress stalemate</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Richard Milne in Oslo, Andrew Ward in London and Alex Barker in Brussels" date="May 6, 2014 11:00 pm" url="http://www.ft.com/cms/s/0/e156005e-d531-11e3-adec-00144feabdc0.html"><headline>Sweden offers cautionary tale to UK over potential Pfizer deal</headline><body><![CDATA[Pfizer''s bid for AstraZeneca has so far drawn the most scrutiny in the UK. But the company''s other home market  Sweden  offers a lesson in what can happen when big drug companies are sold to foreign rivals.</p>
Sweden oversaw the sale of both Astra and Pharmacia  the crown jewels of its pharmaceutical industry  at the end of the 1990s, losing the headquarters of both. Pharmacia was eventually bought by Pfizer in a $60bn deal in 2002, but still some rancour lingers.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Alex Barker in Brussels and Andrew Ward and Elizabeth Rigby in London" date="May 6, 2014 8:31 pm" url="http://www.ft.com/cms/s/0/749be8ac-d531-11e3-adec-00144feabdc0.html"><headline>Swedish minister warns over Pfizer''s plans for AstraZeneca</headline><body><![CDATA[Shut the front door: Jefferies analyst Jeffrey Holford characterised the overly optimistic'' AstraZeneca revenue forecasts on Tuesday as an obvious defence tactic''Getty]]> </body></entry><entry author="By Elizabeth Rigby, Andrew Ward and Kiran Stacey" date="May 6, 2014 8:20 pm" url="http://www.ft.com/cms/s/0/37a8cf50-d545-11e3-adec-00144feabdc0.html"><headline>David Cameron''s party advisers had been paid by Pfizer</headline><body><![CDATA[Reuters]]> </body></entry><entry author="By Jonathan Guthrie" date=" May 6, 2014 11:02 am" url="http://www.ft.com/cms/s/0/00450d32-d502-11e3-adec-00144feabdc0.html"><headline>Pfizer''s 2014 tax cut matters more than AZ''s 2023 sales</headline><body><![CDATA[It is safe to predict that 2023 will be a landmark year for Lombard, as for AstraZeneca, which forecasts revenues will be 76 per cent higher at $45bn. Following a buyout, this column will have become a multinational media empire run from a yacht moored in Bora Bora, while this columnist will have mastered cold fusion and regrown a full head of hair. </p>
The safeness of these predictions resides not in their accuracy, but in the low probability that anyone will remember them nine years from now and complain if they were wrong. So sales estimates published by the Anglo-Swedish drugmaker are best interpreted as an artefact of its battle to make would-be acquirer Pfizer offer more money or sling its hook.</p>
]]> </body></entry><entry author="By Sam Fleming" date="May 5, 2014 8:52 pm" url="http://www.ft.com/cms/s/0/c959a6e8-d3ad-11e3-8d23-00144feabdc0.html"><headline>Pfizer faces trickier takeover rules</headline><body><![CDATA[In its pursuit of its quarry, Pfizer will have to negotiate UK takeover rules that have become trickier to navigate since the start of the decade. </p>
The political controversy over Kraft''s takeover of Cadbury, the confectioner, in 2010, and a subsequent speech by the UK company''s former chairman Sir Roger Carr, led to revisions of the Takeover Code in 2011 to strengthen the position of target companies and force bidders to put more information into the public domain. </p>
]]> </body></entry><entry author="By George Parker, Political Editor" date="May 5, 2014 6:38 pm" url="http://www.ft.com/cms/s/0/47071158-d466-11e3-bf4e-00144feabdc0.html"><headline>Downing St under pressure to recalibrate reaction on Pfizer bid</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By George Parker and Andrew Ward" date="May 5, 2014 7:57 pm" url="http://www.ft.com/cms/s/0/0ca7ff46-d44c-11e3-a122-00144feabdc0.html"><headline>AstraZeneca urges David Cameron to be neutral over Pfizer bid</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Andrew Ward" date="May 4, 2014 6:39 pm" url="http://www.ft.com/cms/s/0/ba383d00-d399-11e3-b0be-00144feabdc0.html"><headline>Pfizer break-up may follow AstraZeneca deal</headline><body><![CDATA[Pfizer has spent the past week setting out its vision to create a transatlantic pharmaceuticals powerhouse through its proposed 63bn takeover of AstraZeneca.</p>
Yet many analysts and investors believe the US group''s interest in its UK rival is less about empire-building and more about fattening up Pfizer for a break-up.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Jim Pickard and Andrew Ward in London" date="May 4, 2014 7:13 pm" url="http://www.ft.com/cms/s/0/c4157c5c-d36c-11e3-b0be-00144feabdc0.html"><headline>Political row intensifies over Pfizer bid for AstraZeneca</headline><body><![CDATA[Newscast]]> </body></entry><entry author="By Andrew Jack and Clive Cookson" date="May 2, 2014 11:01 pm" url="http://www.ft.com/cms/s/0/6f71c502-d20e-11e3-97a6-00144feabdc0.html"><headline>Bid puts Pfizer''s DNA under microscope</headline><body><![CDATA[If companies could be said to have DNA, then Pfizer''s could be encoded with the message acquire to survive. While other pharmaceutical groups have grown through developing and commercialising their own products, the US giant has maintained its leading position in large part through takeovers.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By George Parker and Jim Pickard" date="May 2, 2014 6:45 pm" url="http://www.ft.com/cms/s/0/aecffcc0-d202-11e3-8b5b-00144feabdc0.html"><headline>Cameron green flag for Pfizer''s proposed AstraZeneca purchase</headline><body><![CDATA[David Cameron on Friday effectively raised a green flag for Pfizer''s proposed purchase of AstraZeneca, in a sign to his critics that he has no intention of closing Britain''s doors to 63bn of potential inward investment.</p>
Lord Heseltine, the former Tory deputy prime minister, has argued that Britain needs to build up its legal defences against foreign takeovers, after the Pfizer bid served as a reminder that the UK has few national interest get-outs to stop such bids.</p>
]]> </body></entry><entry author="By Jonathan Guthrie" date=" May 2, 2014 12:17 pm" url="http://www.ft.com/cms/s/0/7c426aba-d1e7-11e3-8ff4-00144feabdc0.html"><headline>Yours noncommittally, Pfizer</headline><body><![CDATA[FT City columnist Lombard imagines the comfort letter Ian Read, straight-talking boss of Pfizer, might have sent to David Cameron about his bid for AstraZeneca if PR experts had not edited it first.
</p>
Dear Prime Minister,</p>
]]> </body></entry><entry author="By George Parker, Political Editor" date="May 2, 2014 10:40 am" url="http://www.ft.com/cms/s/0/7fac26e2-d1d7-11e3-8ff4-00144feabdc0.html"><headline>David Cameron welcomes Pfizer assurances on UK jobs and research</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Jim Pickard, Chief Political Correspondent" date="May 2, 2014 9:13 am" url="http://www.ft.com/cms/s/0/908da0c2-d1cc-11e3-8ff4-00144feabdc0.html"><headline>Chuka Umunna attacks Pfizer for record of asset-stripping''</headline><body><![CDATA[Chuka Umunna, the shadow business secretary, has stepped up his criticism of the potential purchase of AstraZeneca and attacked US bidder Pfizer''s record of asset-stripping in previous takeovers.</p>
Pfizer has a very poor record on previous acquisitions, he said. There is its acquisition of Warner-Lambert in 2000 in the US; Pharmacia in Sweden in 2003; and Wyeth in the US in 2000, and that led to deep cuts in the research facilities, it led to intellectual asset-stripping and look at the RD, because RD is absolutely crucial here.</p>
]]> </body></entry><entry author="By Andrew Ward, David Oakley and George Parker" date="May 2, 2014 10:56 pm" url="http://www.ft.com/cms/s/0/f7be0938-d1bf-11e3-8ff4-00144feabdc0.html"><headline>AstraZeneca rejects Pfizer''s sweetened bid</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Andrew Ward and Elizabeth Rigby in London and Ed Hammond in New York" date="May 1, 2014 6:29 pm" url="http://www.ft.com/cms/s/0/f1c22f12-d14e-11e3-81e0-00144feabdc0.html"><headline>Pfizer plans to raise AstraZeneca offer</headline><body><![CDATA[Pfizer is planning to sweeten its 60bn takeover approach for AstraZeneca in an attempt to increase pressure on its UK rival to enter talks to create the world''s biggest drugmaker. </p>
Ian Read, Pfizer''s chairman and chief executive, returned to New York on Thursday to plot his next move after two days of meetings in London aimed at winning support from the UK government and the City for the biggest foreign takeover of a UK company in history.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Jonathan Guthrie" date=" May 1, 2014 11:19 am" url="http://www.ft.com/cms/s/0/fa7f29bc-d111-11e3-bdbb-00144feabdc0.html"><headline>Pfizer''s Read revives vision of all-conquering corporate</headline><body><![CDATA[Britain''s science base would be devastated if Pfizer bought AstraZeneca, according to Lord Sainsbury. But that is nothing to how devastated many investors would feel if Pfizer walked away, now that the US drugs group has proposed paying 50 per share in cash and stock. They will be grateful the government does not have the reserve powers to block foreign takeovers proposed by Lord Heseltine, an adviser to David Cameron.</p>
Financial and political arguments interweave in the debate over the prospective $100bn-plus drugs sector takeover. These highlight the resurgence of the footloose multinational as a force to be reckoned with after a post-crash hiatus when the state reasserted its power.</p>
]]> </body></entry><entry author="By Delphine Strauss" date="May 1, 2014 8:14 am" url="http://www.ft.com/cms/s/0/7b96d6e2-d0fb-11e3-9f90-00144feabdc0.html"><headline>Why the Pfizer bid is propelling the pound</headline><body><![CDATA[Should currency investors care about corporate mergers and acquisitions? The pound''s bounce week suggests at least some of them do. Despite the hurdles Pfizer has to overcome in its pursuit of the UK''s AstraZeneca, confirmation of its interest helped to propel sterling to a near five-year high.</p>
The announcement effect was clear in Monday''s trading, even though opinion is split over the extent to which the last big deal involving a UK company  Vodafone''s sale of its stake in US Verizon Wireless, completed two months ago  may have influenced the exchange rate.</p>
You need JavaScript active on your browser in order to see this video.</p>]]> </body></entry><entry author="By Elizabeth Rigby, Deputy Political Editor" date="April 30, 2014 10:44 pm" url="http://www.ft.com/cms/s/0/d0ae969c-d088-11e3-8b90-00144feabdc0.html"><headline>UK premier picks top dealmakers for Pfizer-AstraZeneca talks</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Andrew Ward, David Oakley and Elizabeth Rigby" date="April 30, 2014 7:24 pm" url="http://www.ft.com/cms/s/0/b45b749e-d077-11e3-9a81-00144feabdc0.html"><headline>AstraZeneca''s Johansson hits at Pfizer big is better'' bid</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Sarah Gordon, Europe business editor" date=" April 30, 2014 3:09 pm" url="http://www.ft.com/cms/s/0/d2103d8e-d046-11e3-af2b-00144feabdc0.html"><headline>Pfizer-AstraZeneca marriage divides opinion</headline><body><![CDATA[Reuters]]> </body></entry><entry author="By Vanessa Houlder" date="April 29, 2014 8:30 pm" url="http://www.ft.com/cms/s/0/c7dc2092-cfb7-11e3-a2b7-00144feabdc0.html"><headline>Patent box holds key to Pfizer-AZ deal''s attraction</headline><body><![CDATA[The patent box  a big UK tax break for innovative companies  is an important part of the attraction for Pfizer as it stalks AstraZeneca and eyes a move of its tax domicile to Britain.</p>
Announced in the 2012 budget, the government measure aims to stimulate research and development in the UK by offering a special 10 per cent tax rate on profits earned from patents. The relief is being phased in over four years from April 2013.</p>
]]> </body></entry><entry author="By Andrew Ward, Pharmaceuticals Correspondent" date="April 29, 2014 7:54 pm" url="http://www.ft.com/cms/s/0/ce653d6c-cfb3-11e3-9b2b-00144feabdc0.html"><headline>Pfizer chief executive pins faith on its powers of persuasion</headline><body><![CDATA[Newscast]]> </body></entry><entry author="By Andrew Ward and George Parker" date="April 29, 2014 9:35 pm" url="http://www.ft.com/cms/s/0/e354386e-cfa3-11e3-9b2b-00144feabdc0.html"><headline>Pfizer flies in to clear path for 60bn AstraZeneca takeover</headline><body><![CDATA[Bloomberg<p>Ian Read, Pfizer CEO</p>]]> </body></entry><entry author="By Andrew Ward and Vanessa Houlder in London and Barney Jopson in Washington" date="April 28, 2014 7:23 pm" url="http://www.ft.com/cms/s/0/0cad0dd4-ce9c-11e3-ac8d-00144feabdc0.html"><headline>Pfizer ignites pharma takeover battle</headline><body><![CDATA[
Reuters]]> </body></entry><entry author="By Ed Hammond in New York and Andrew Ward in London" date="April 27, 2014 11:54 pm" url="http://www.ft.com/cms/s/0/c6b1c44a-ce3d-11e3-9dfd-00144feabdc0.html"><headline>Pfizer renews bid interest in AstraZeneca</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Andrew Ward and Jim Pickard" date="April 21, 2014 6:54 pm" url="http://www.ft.com/cms/s/0/5dfe4752-c974-11e3-89f8-00144feabdc0.html"><headline>Pfizer approach raises questions over UK''s takeover stance</headline><body><![CDATA[AstraZeneca''s products may not have the same emotional appeal to Britons as Dairy Milk chocolate, but any takeover of the drugmaker could have more far-reaching implications than Kraft''s 11.6bn acquisition of Cadbury in 2010.</p>
That deal prompted intense debate over whether UK takeover rules left British companies too open to foreign takeover.</p>
]]> </body></entry><entry author="By Andrew Ward in London and Ed Hammond in New York" date="April 22, 2014 9:07 am" url="http://www.ft.com/cms/s/0/27fbd07c-c94a-11e3-bba1-00144feabdc0.html"><headline>AstraZeneca US shares jump as details of Pfizer talks revealed</headline><body><![CDATA[Bloomberg<p>Pascal Soriot, AstraZeneca chief</p>]]> </body></entry><entry author="By Eric Platt in New York" date="April 7, 2014 10:13 pm" url="http://www.ft.com/cms/s/0/bbc23aa6-be70-11e3-a1bf-00144feabdc0.html"><headline>Pfizer falls as treatment trial disappoints</headline><body><![CDATA[Pfizer, the US pharmaceuticals group, weakened on Monday after results of a mid-stage experimental breast cancer treatment trial disappointed investors, despite meeting the primary goal of the study.</p>
The trial of palbociclib, an oral medication, has been closely watched by market participants, many of whom believe it could top $5bn in sales at its peak if approved.</p>
]]> </body></entry><entry author="By Eric Platt in New York" date="February 3, 2014 9:47 pm" url="http://www.ft.com/cms/s/0/6707fd3a-8cf6-11e3-8b82-00144feab7de.html"><headline>Pfizer bucks declines on cancer drug trial hopes</headline><body><![CDATA[Shares in US pharmaceuticals group Pfizer rallied on Monday after a mid-stage drug trial of an experimental breast cancer treatment successfully met its goals of delaying the progression of symptoms in women with locally advanced or newly diagnosed metastatic cancer.</p>
The trial of palbociclib, an oral medication, has been closely watched by investors and analysts who believe it could top $5bn in sales if approved. Analysts at Morgan Stanley have said palbociclib could top Pfizer''s blockbuster Lipitor drug at its peak if successful.</p>
]]> </body></entry><entry author="By Andrew Ward, Pharmaceuticals Correspondent" date="January 28, 2014 6:54 pm" url="http://www.ft.com/cms/s/0/e35c47a6-8841-11e3-85a2-00144feab7de.html"><headline>Pfizer sales decline on increased competition from generics</headline><body><![CDATA[Pfizer reported better than expected fourth-quarter profit on Tuesday, but revenues fell as the maker of Lipitor and Viagra faced increased competition from cheaper generic medicines.</p>
Investors are awaiting progress reports on a series of new drugs under development by the biggest US pharmaceuticals group as it scrambles to offset the loss of patent protection on some of its blockbuster brands.</p>
]]> </body></entry><entry author="By Andrew Jack" date="October 29, 2013 6:49 pm" url="http://www.ft.com/cms/s/0/d4c34b5e-40c5-11e3-8775-00144feabdc0.html"><headline>Pfizer to publish separate results for its 3 business units</headline><body><![CDATA[Pfizer confirmed it is to separately publish the financial results of its three business divisions from the first quarter of next year, in a move further fuelling speculation that the US pharmaceutical company is exploring a sale or spin-off of some operations.</p>
In a commitment seen by some analysts as a precursor to a divestment  notably of its established business of off-patent products  it will begin releasing separate results for the units, creating the option of a quoted spinout by as soon as 2017 following the requirement for three years of financial data.</p>
]]> </body></entry><entry author="By Andrew Jack" date="July 30, 2013 11:28 pm" url="http://www.ft.com/cms/s/0/a5732036-f962-11e2-86e1-00144feabdc0.html"><headline>Pfizer finalises overselling settlement</headline><body><![CDATA[Pfizer has finalised a criminal and civil settlement worth $491m with US authorities for alleged overselling of a transplant drug produced by Wyeth, the company it acquired in 2009.</p>
The US pharmaceutical group agreed a $234m fine and asset forfeiture with the Department of Justice as well as $247m in civil penalties, for which it had made a provision late last year.</p>
]]> </body></entry><entry author="By Andrew Jack in London" date="July 30, 2013 4:10 pm" url="http://www.ft.com/cms/s/0/971cdea8-f914-11e2-a6ef-00144feabdc0.html"><headline>Pfizer earnings hit by sales drop</headline><body><![CDATA[Pfizer reported earnings a share down 5 per cent in the second quarter on sales down 7 per cent following patent expirations, as it 
revealed 
details of plans to split reporting into three separate business units from next year.</p>
The US pharmaceutical group maintained guidance, despite the loss of exclusivity in many markets of Lipitor, its cholesterol-lowering blockbuster treatment. It reported earnings down to $0.56 a share on the same period last year, on sales of $13bn.</p>
]]> </body></entry><entry author="By Sally Davies" date="August 27, 2014 7:48 pm" url="http://www.ft.com/cms/s/0/cd3fd90e-2de3-11e4-b330-00144feabdc0.html"><headline>Monitise signs partnership deal with IBM</headline><body><![CDATA[British mobile money company Monitise has signed a partnership agreement with IBM in the latest sign that technology groups are pushing further into the lucrative financial services sector.</p>
News of the agreement sent Monitise shares up about 14 per cent to a closing price of 48.4p. Monitise shares had fallen precipitously in the preceding months, to half the 80p highs they attained earlier in the year.</p>
]]> </body></entry><entry author="By Daniel Thomas, Telecoms Correspondent" date="July 24, 2014 3:30 pm" url="http://www.ft.com/cms/s/0/0da6dfe6-1265-11e4-93a5-00144feabdc0.html"><headline>BlackBerry looks to partnerships to compete with Apple and IBM venture</headline><body><![CDATA[PR Photo<p>BlackBerry sales have plunged in recent years</p>]]> </body></entry><entry author="By Hannah Kuchler in San Francisco" date="July 17, 2014 11:03 pm" url="http://www.ft.com/cms/s/0/5111614e-0df0-11e4-85ab-00144feabdc0.html"><headline>IBM beats earnings and revenue expectations</headline><body><![CDATA[Getty]]> </body></entry><entry author="By Tim Bradshaw and Richard Waters in San Francisco" date="July 15, 2014 10:21 pm" url="http://www.ft.com/cms/s/0/b3b59c60-0c61-11e4-943b-00144feabdc0.html"><headline>Apple and IBM take on corporate market together</headline><body><![CDATA[Apple/Paul Sakuma]]> </body></entry><entry author="By Richard Waters in San Francisco" date="July 9, 2014 10:00 pm" url="http://www.ft.com/cms/s/0/c7e07182-077b-11e4-b1b0-00144feab7de.html"><headline>IBM sets out $3bn chip development plans</headline><body><![CDATA[Getty]]> </body></entry><entry author="By Hannah Kuchler in San Francisco" date="April 16, 2014 9:55 pm" url="http://www.ft.com/cms/s/0/17af0dac-c5a7-11e3-a7d4-00144feabdc0.html"><headline>IBM hit by costs of restructuring</headline><body><![CDATA[IBM suffered a more than 20 per cent fall in net income in the first quarter, as revenues slid and a massive restructuring programme cost the computing company almost $900m.</p>
Shares dipped 4 per cent in after-hours trading in New York even as the company met analysts expectations, reporting non-GAAP earnings per share of $2.54, down 15 per cent from the first quarter of 2013. Net income on a GAAP basis fell 22 per cent to $2.6bn.</p>
]]> </body></entry><entry author="By Tom Mitchell in Beijing" date="March 11, 2014 2:49 pm" url="http://www.ft.com/cms/s/0/8c0da1dc-a90e-11e3-9b71-00144feab7de.html"><headline>Lenovo to inherit half-empty IBM factory as workers quit</headline><body><![CDATA[Reuters<p>IBM workers protest at a factory in Shenzhen</p>]]> </body></entry><entry author="By Tom Mitchell and Charles Clover in Beijing" date="March 6, 2014 3:24 am" url="http://www.ft.com/cms/s/0/d43df3c6-a4db-11e3-b915-00144feab7de.html"><headline>IBM workers strike in China over terms of Lenovo takeover</headline><body><![CDATA[Reuters]]> </body></entry><entry author="By Richard Waters in San Francisco" date="February 28, 2014 10:43 pm" url="http://www.ft.com/cms/s/0/46e9c74a-a0c4-11e3-a72c-00144feab7de.html"><headline>IBM braced for fresh US job cuts</headline><body><![CDATA[A $1bn global restructuring aimed at maintaining IBM''s earnings growth in the face of flagging revenues reached the US this week, with more job cuts in the company''s home market.</p>
The computer group would not disclose how many of the 431,212 workers it had at the end of last year would eventually lose their jobs in the shake-up, which has yet to hit some other countries.</p>
]]> </body></entry><entry author="By Richard Waters in San Francisco" date="February 7, 2014 7:09 pm" url="http://www.ft.com/cms/s/0/f563bea0-8fa5-11e3-9cb0-00144feab7de.html"><headline>Semiconductor sale a vital part of IBM''s strategic realignment</headline><body><![CDATA[Getty]]> </body></entry><entry author="By Ed Hammond in New York and Richard Waters in San Francisco" date="February 7, 2014 2:20 am" url="http://www.ft.com/cms/s/0/7451e31a-8f90-11e3-9cb0-00144feab7de.html"><headline>IBM eyes sale of semiconductor arm</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Charles Clover in Beijing" date="January 23, 2014 12:22 pm" url="http://www.ft.com/cms/s/0/99e05aa8-8419-11e3-9903-00144feab7de.html"><headline>Lenovo to buy IBM server unit for $2.3bn</headline><body><![CDATA[Chinese computer maker Lenovo announced it would acquire IBM''s industry-standard x86 server business, in an agreement valued at $2.3bn in cash and stock.</p>
The likely deal offered IBM a long sought exit from the low-end server business  it had originally approached Lenovo about selling the business last year. IBM''s top executives on Tuesday volunteered to give up their bonuses for 2013 after announcing a 5 per cent fall in revenues for the fourth quarter, though net income rose by 6 per cent.</p>
]]> </body></entry><entry author="By Richard Waters" date=" January 22, 2014 7:27 pm" url="http://www.ft.com/cms/s/0/7f45ff04-82f7-11e3-8119-00144feab7de.html"><headline>IBM must keep head above the clouds to claim glory</headline><body><![CDATA[It falls to every new IBM chief executive to reinvent one of America''s most venerable corporate icons.</p>
After Lou Gerstner countered a decline in hardware sales with a faster move into software and services in the 1990s, Sam Palmisano spent the next decade contending with the threat of Indian IT companies and open-source software.</p>
]]> </body></entry><entry author="By Richard Waters in San Francisco" date="January 21, 2014 9:51 pm" url="http://www.ft.com/cms/s/0/337e7c0c-82e5-11e3-9d7e-00144feab7de.html"><headline>IBM top tier waive bonuses after sales slide</headline><body><![CDATA[IBM chief executive Ginni Rometty and other senior executives volunteered to give up their bonuses for 2013 as the US technology conglomerate revealed it had suffered an accelerating revenue decline in the final months of last year.</p>
Another slump in the company''s hardware business lay behind the latest in a string of sales disappointments. The decline has fuelled worries on Wall Street that IBM is in danger of being left behind in the shift to cloud computing, as customers take advantage of a new generation of services to cut spending on computers and other hardware. </p>
]]> </body></entry><entry author="By Ed Hammond and Richard Waters" date="January 21, 2014 12:44 am" url="http://www.ft.com/cms/s/0/4485a7ae-8200-11e3-87d5-00144feab7de.html"><headline>IBM looks to sell low-end server business</headline><body><![CDATA[IBM is considering selling its x86 business in a deal that would mark a long-awaited exit from the low-end server market for the US technology company.</p>
IBM, which has a market value of more than $200bn, had tried unsuccessfully to sell the business last year to Lenovo, the Chinese computer maker, according to reports.</p>
]]> </body></entry><entry author="By Richard Waters in San Francisco" date="January 17, 2014 2:22 am" url="http://www.ft.com/cms/s/0/2280fe16-7f16-11e3-a2a7-00144feabdc0.html"><headline>IBM plans rapid cloud expansion</headline><body><![CDATA[IBM has laid out plans for a rapid expansion of its data centres around the world as it races to make up for lost time and prevent internet companies such as Amazon from cornering the fast-growing cloud computing market.</p>
The US technology group said late on Thursday that it would spend $1.2bn in 2014 to add 13 new data centres, taking the total to 40. The move follows its $2bn purchase last year of SoftLayer, whose software is a building block for running cloud services, and signals the latest step in Big Blue''s rethink of its position in cloud computing.</p>
]]> </body></entry><entry author="By Richard Waters in San Francisco" date="January 9, 2014 3:29 am" url="http://www.ft.com/cms/s/0/e137aac6-78db-11e3-831c-00144feabdc0.html"><headline>IBM to create new $1bn Watson business unit</headline><body><![CDATA[IBM is to carve out Watson, its question-and-answer cognitive computing effort, as a new business unit and put $1bn of investment behind the initiative as it seeks new ways to revive flagging growth.</p>
]]> </body></entry><entry author="By James Crabtree in Mumbai" date="December 3, 2013 1:23 pm" url="http://www.ft.com/cms/s/0/1eccbb9e-5c15-11e3-b4f3-00144feabdc0.html"><headline>IBM launches legal challenge against India tax claims</headline><body><![CDATA[IBM has launched a legal challenge over an estimated $800m tax demand from India''s revenue department  becoming the latest major western multinational to find itself ensnared in a payment dispute in Asia''s third-largest economy. </p>
The US-based technology group is appealing against the tax bill to India''s dispute resolution panel, an arbitration body often used by international businesses, according to people familiar with the situation. </p>
]]> </body></entry><entry author="By Richard Waters in San Francisco" date="November 14, 2013 6:55 am" url="http://www.ft.com/cms/s/0/e64eca88-4cf0-11e3-9f40-00144feabdc0.html"><headline>IBM''s Watson artificial intelligence to get new homes with rivals</headline><body><![CDATA[IBM has opened up its Watson artificial intelligence technology for use by other software developers, potentially paving the way for a new generation of online services capable of responding to their users in smarter and more natural ways.</p>
First shown off two years ago competing in the Jeopardy
 question-and-answer television game show against human contestants, Watson was built as a showcase for IBM breakthroughs in technologies such as those enabling computers to better understand human interaction.</p>
]]> </body></entry><entry author="By Jason Abbruzzese in New York" date="October 17, 2013 5:27 pm" url="http://www.ft.com/cms/s/0/b9138b80-3738-11e3-9603-00144feab7de.html"><headline>IBM decline hits US tech sector</headline><body><![CDATA[The SP500 closed at a record high and hit a new intraday high on Thursday but a decline by IBM and Goldman Sachs due to downbeat earnings reports prevented the Dow Jones Industrial Average from joining the rally.</p>
IBM shares fell 6.4 per cent to $174.78, the lowest level in about two years.</p>
]]> </body></entry><entry author="By Richard Waters in San Francisco" date="October 16, 2013 10:09 pm" url="http://www.ft.com/cms/s/0/9623e418-36a1-11e3-aaf1-00144feab7de.html"><headline>IBM blames China for slide in revenues</headline><body><![CDATA[IBM blamed stalling sales in China, caused by uncertainty ahead of the country''s pending economic reform plan, for a large part of an unexpected slide in revenues in the latest quarter, wiping 6 per cent from its market value late on Wednesday.</p>
It was a setback for the US technology group''s so-called growth markets unit  a term meant to encompass emerging countries that represent the best hopes for expansion  as sales fell by 9 per cent in the quarter.</p>
]]> </body></entry><entry author="By Paul Taylor in New York" date="August 15, 2013 5:55 pm" url="http://www.ft.com/cms/s/0/ad066f6e-05c5-11e3-ad01-00144feab7de.html"><headline>IBM buys Israeli cyber security company Trusteer</headline><body><![CDATA[IBM is buying Trusteer, a private Israeli cloud-based cyber security software provider that counts many of the largest US and UK banks among its customers.</p>
Financial terms of the transaction were not disclosed, but IBM, which will form a cyber security software lab in Israel with more than 200 researchers from both companies as part of the deal, is reported to be paying between $800m and $1bn for Trusteer.</p>
]]> </body></entry><entry author="By Henry Mance" date="August 1, 2013 12:21 pm" url="http://www.ft.com/cms/s/0/001291ca-fa94-11e2-a7aa-00144feabdc0.html"><headline>SEC investigates IBM''s cloud revenues</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Tim Bradshaw in San Francisco" date="July 17, 2013 10:29 pm" url="http://www.ft.com/cms/s/0/a68d13ec-ef1b-11e2-9269-00144feabdc0.html"><headline>IBM lifts outlook after beating forecasts</headline><body><![CDATA[Bloomberg]]> </body></entry><entry author="By Richard Waters in San Francisco" date="June 19, 2013 5:46 pm" url="http://www.ft.com/cms/s/0/9ecf5a64-d8cf-11e2-a6cf-00144feab7de.html"><headline>IBM looks beyond the IT department for fresh growth</headline><body><![CDATA[Bloomberg]]> </body></entry></news>